Please assess the completion status of the following clinical trial:

Trial Title: Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has a relapsing form of Multiple Sclerosis (MS); diagnosis of MS is in accordance with the McDonald criteria~* Participant is eligible for interferon therapy~* Participant is between 18 and 60 years old~* Participant has an Expanded Disability Status Scale (EDSS) \< 6.0.~* Participant is willing to follow study procedures~* Participant has given written informed consent~* Female participants must be neither pregnant nor breast-feeding, and must lack childbearing potential, as defined by either:~* Being post-menopausal or surgically sterile, or~* Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study.~* Confirmation that the participant is not pregnant must be established by a negative serum or urinary hCG test within 7 days prior to start of study treatment. A pregnancy test is not required if the participant is post-menopausal or surgically sterile.~Exclusion Criteria:~* Participant has a Clinically Isolated Syndrome (CIS), Primary Progressive MS, or Secondary Progressive MS without superimposed relapses.~* Participant had any prior interferon beta therapy (either beta-1b or beta-1a)~* Participant has an ongoing MS relapse.~* Participant received any other approved disease modifying therapy for MS (e.g. glatiramer acetate) or any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 1(SD1).~* Participant had prior use of cladribine or has previously received total lymphoid irradiation.~* Participant received oral or systemic corticosteroids or adrenocorticotropic hormone (ACTH) within 30 days of SD1.~* Participant received intravenous immunoglobulins or underwent plasmapheresis within the 6 months prior to SD1.~* Participant received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, Campath) within the 12 months prior to SD1.~* Participant requires chronic or monthly pulse corticosteroids during the study.~* Participant received any investigational drug or experimental procedure within 12 weeks of SD1.~* Participant has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase \> 2.5 times the upper limit of the normal values.~* Participant has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal.~* Participant suffers from current autoimmune disease.~* Participant suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol.~* Participant has a known allergy to IFN or the excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Rebif New Formulation Cohort (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete